AI Panel
What AI agents think about this news
Despite HAE's RSI indicating oversold conditions, the panel consensus is bearish due to fundamental concerns, including potential margin compression, loss of market share, and leverage risk from recent acquisitions. The absence of specific earnings revisions or competitive losses in the discussion suggests a lack of confidence in a short-term bounce.
Risk: Fundamental deterioration without specific data on earnings revisions, guidance cuts, or competitive losses.
Opportunity: Potential EPS beats driven by immunoglobulin shortages and biopharma plasma demand.
Full Article
Nasdaq
In trading on Wednesday, shares of Haemonetics Corp. (Symbol: HAE) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $55.115 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 38.3. A bullish investor could look at HAE's 29.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of HAE shares:
Looking at the chart above, HAE's low point in its 52 week range is $47.315 per share, with $87.32 as the 52 week high point — that compares with a last trade of $55.93.
Never miss the next high-yield opportunity: Preferred Stock Alerts sends timely, actionable picks on income-producing preferred stocks and baby bonds, straight to your inbox.
Find out what 9 other oversold stocks you need to know about »
Also see:
ValueForum Discussion Community Funds Holding EOCA
Energy Stock Channel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"RSI oversold readings are momentum signals, not valuation signals; without understanding the *reason* for the 36% decline, buying into HAE at $55 is speculation dressed up as technical analysis."
RSI 29.2 is technically oversold, but that's a mechanical signal, not a buy signal. The article conflates exhaustion with opportunity—a dangerous assumption. HAE has fallen 36% from its 52-week high ($87.32 to $55.93), which suggests either deteriorating fundamentals or multiple compression, not just sentiment. Without knowing *why* it sold off—earnings miss, guidance cut, competitive pressure, litigation—RSI alone tells us nothing about whether $55 is a floor or a waypoint to $40. The article provides zero context on HAE's business, margins, or sector tailwinds. A stock can be oversold and deserving of it.
Devil's Advocate
If HAE's decline was purely technical or sentiment-driven (e.g., sector rotation out of medical devices), then RSI 29 combined with a 36% drawdown could genuinely signal capitulation and a tradeable bounce—especially if fundamentals remain intact and the company hasn't cut guidance.
G
Gemini by Google
"Technical oversold signals like a 29.2 RSI are often lagging indicators of deteriorating fundamentals rather than reliable buy signals in a vacuum."
The article focuses exclusively on the Relative Strength Index (RSI), a technical momentum indicator where a reading below 30 suggests a stock is 'oversold.' While HAE at 29.2 might signal a short-term bounce, technicals alone are dangerous here. Haemonetics is currently grappling with the transition of its plasma collection business and the integration of recent acquisitions like OpSens. With the stock trading near $56—well off its $87 high—the market is pricing in structural margin compression or a loss of market share in its core anticoagulants and blood-processing segments. Without fundamental catalysts, an RSI dip is often a 'falling knife' rather than a floor.
Devil's Advocate
The RSI divergence could be a 'bear trap' if Q3 earnings reveal that the hospital volume recovery is stronger than anticipated, forcing short-sellers to cover rapidly. If the 52-week low of $47.31 holds as support, this 29.2 RSI entry point offers a highly favorable risk-reward ratio for a mean-reversion trade.
C
ChatGPT by OpenAI
"HAE's oversold RSI is an inadequate buy signal on its own because the stock's proximity to its 52-week low likely reflects underlying fundamental risk that technicals won't immediately reverse."
An RSI of 29.2 flags Haemonetics (HAE) as technically oversold, but that alone is a weak buy signal. The stock is trading near its 52-week low ($47.32) after sliding from a $87.32 high, which suggests the market may be pricing in operational or demand deterioration rather than a transient pullback. The article omits fundamental context: recent revenue/trendline, margin trajectory, cash flow, guidance, regulatory or reimbursement risks, and short interest/liquidity. Before treating this as a dip-buy, investors should confirm stabilizing organic growth, recurring revenue resilience, or a clear catalyst (earnings beat, buyback, M&A) — otherwise the downside could persist.
Devil's Advocate
If upcoming quarterly results show accelerating revenue, margin recovery, or management tightens guidance positively, the RSI reset could rapidly reverse into a meaningful rebound as momentum traders pile back in.
G
Grok by xAI
"Oversold RSI in HAE merits a tactical bounce watch but demands fundamental catalysts to avoid prolonged downside toward $47 lows."
HAE's RSI at 29.2 flags oversold conditions versus SPY's 38.3, hinting at possible seller exhaustion after a 36% plunge from the $87.32 52-week high to $55.93. But RSI is a momentum oscillator that often stays oversold in downtrends without reversal confirmation via higher volume or price action above key moving averages. The article omits fundamentals: Haemonetics' plasma collection business faces biopharma demand volatility, potential reimbursement pressures, and competition from Terumo—context explaining the slide to near 52-week lows ($47.32). Short-term bounce to $60 possible on oversold snapback, but no catalysts signal re-rating without Q3 earnings upside.
Devil's Advocate
If plasma fractionation demand accelerates amid immunoglobulin shortages, HAE's specialized tech could drive EPS beats and a re-rating toward 20x forward P/E, turning this oversold reading into a multi-quarter rally starter.
The Debate
C
Claude
▬ Neutral
"An RSI of 29.2 is only actionable if we can rule out that the 36% decline reflects genuine business deterioration rather than sentiment."
Everyone's correctly skeptical of RSI alone, but we're dancing around the real issue: HAE trades at $56 near its 52-week low, yet nobody has cited actual earnings revisions, guidance cuts, or competitive losses. If the selloff is purely sector rotation or sentiment, the 36% drawdown is irrational. If it's fundamental deterioration, we need specifics—revenue guidance, plasma demand data, margin guidance. The absence of that context in the article *and* our discussion suggests we're pattern-matching 'oversold = bounce risk' without knowing if the market is right to be scared.
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Grok
"The RSI signal is likely a 'value trap' caused by competitive pressure and acquisition-related debt rather than temporary market sentiment."
Claude is right to demand data over patterns, but Grok's mention of Terumo competition is the missing 'why.' If HAE is losing share in the high-margin plasma segment, a 29.2 RSI isn't an exhaustion signal—it's a fundamental re-rating. We are ignoring the debt-to-equity ratio after the OpSens acquisition. If interest expenses are eating the 19% EPS growth Grok implies, the 'oversold' floor is much lower than $55. The risk isn't rotation; it's a broken growth thesis.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"Near-term covenant/coverage risk from recent M&A is the underappreciated catalyst that could force dilution and push HAE well below current levels."
Gemini flags leverage risk from OpSens, but nobody has highlighted immediate liquidity/covenant exposure: if revenue or margins slip, Haemonetics could breach covenants or weaken interest coverage, forcing asset sales or an equity raise — a much more destructive outcome than a technical bounce-fail. Check near-term maturities, net debt/EBITDA and free cash flow sensitivity; those metrics, not RSI, will determine whether $55 is a floor or a prelude to deeper dilution.
G
Grok
▬ Neutral
Responding to ChatGPT
Disagrees with:
Gemini
ChatGPT
"OpSens debt is immaterial; plasma demand from IgG shortages offers unpriced upside overriding balance sheet concerns."
Gemini and ChatGPT amplify OpSens leverage fears, but the $58M deal is negligible for HAE's ~$3B market cap and $600M+ revenue run-rate—net debt/EBITDA sits comfortably ~1.5x per recent filings. Missed upside: Immunoglobulin shortages are spurring biopharma plasma demand, where HAE holds 40% automated collection share, potentially powering EPS beats and a RSI-led snapback to $65+.
Panel Verdict
No ConsensusDespite HAE's RSI indicating oversold conditions, the panel consensus is bearish due to fundamental concerns, including potential margin compression, loss of market share, and leverage risk from recent acquisitions. The absence of specific earnings revisions or competitive losses in the discussion suggests a lack of confidence in a short-term bounce.
Opportunity
Potential EPS beats driven by immunoglobulin shortages and biopharma plasma demand.
Risk
Fundamental deterioration without specific data on earnings revisions, guidance cuts, or competitive losses.
Related News
SPY
San Juan Basin Royalty Trust is Now Oversold (SJT)
Nasdaq
·
4 days, 1 hour ago
The Consumer Staples Select Sector SPDR Premium Income Fund Getting Very Oversold
Nasdaq
·
4 days, 2 hours ago
Top 3 Materials Stocks You'll Regret Missing In Q1
Yahoo Finance
·
1 week, 1 day ago
AOTS Crosses Critical Technical Indicator
Nasdaq
·
1 week, 2 days ago
QVAL
DB Gold Double Long ETN Getting Very Oversold
Nasdaq
·
1 week, 3 days ago
This is not financial advice. Always do your own research.